Rituxan Hycela Alternatives Compared
Rituxan Hycela | Imbruvica | Venetoclax |
|
---|
Rituxan Hycela (hyaluronidase / rituximab) | Imbruvica (ibrutinib) | Venetoclax |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Rituxan Hycela is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate and may be used to treat follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and chronic... View more |
Prescription only
Imbruvica is an oral tablet that may be taken once daily to treat certain types of cancers in adults or to treat chronic Graft Versus Host disease in adults and children older than 1 year. It works... View more |
Prescription only
Prescribed for Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia. venetoclax may also be used for purposes not listed in this medication guide. |
||||||||||||||||
More about Rituxan Hycela (hyaluronidase / rituximab) | More about Imbruvica (ibrutinib) | More about Venetoclax | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Be the first to share your experience with this drug. |
Imbruvica has an average rating of 6.3 out of 10 from a total of 60 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 34% reported a negative effect. |
Venetoclax has an average rating of 8.6 out of 10 from a total of 10 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: Rituxan Hycela side effects in more detail. |
See also: Imbruvica side effects in more detail. |
See also: venetoclax side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
N/A |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Rituxan Hycela prices |
View all Imbruvica prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||
|
|
N/A |
||||||||||||||||
Brand Names | ||||||||||||||||||
N/A |
N/A |
Venclexta | ||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
648 hours (empirically) |
6 hours |
26 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 236 drugs are known to interact with Rituxan Hycela:
|
A total of 457 drugs are known to interact with Imbruvica:
|
A total of 422 drugs are known to interact with venetoclax:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
N/A |
November 13, 2013 |
N/A |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.